ArticleClinical & translational immunology2026
A characterisation of the immune cells in immunocompetent and immunodeficient mice with orthotopic brain tumors.
Article in Clinical & translational immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tumors located in the brain impair the frequency and phenotype of dendritic cells in blood and tumor.iScience · 2026Article
- A characterisation of the immune cells in immunocompetent and immunodeficient mice with orthotopic brain tumors.Clinical & translational immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Glioblastoma is characterised by poor survival with few treatment advances for over 20 years. Immunotherapies, which have transformed treatment of other cancers, have been difficult to apply to glioblastoma because of its highly immune-suppressive microenvironment, and there is a growing appreciation that the disease also induces a global suppression of the systemic immune system. However, immunotherapy research is hampered by the lack of detailed characterisation of the whole immune system in murine brain tumor models, with studies until now having focussed mainly on tumor-infiltrating immune cells. Methods: Here, we have studied common murine models of intracranial brain tumors by using high-parameter flow cytometry and tissue immunofluorescence staining to fully characterise immune cells in the brain, draining lymph node, spleen and bone marrow. Results: The highly immune-compromised NSG mouse models were striking in their many immune perturbations, which extended beyond the known deficits in lymphocytes. Immunocompetent tumor models had significant changes in brain-resident immune cells compared to controls, as expected; however, systemic effects were also observed with significant reductions in subsets of monocytes, macrophages and dendritic cells in the spleen and increases in bone marrow. Conclusion: Our extensive and quantitative characterisation of the immune system in murine models of glioblastoma will allow for a better-informed selection of models and advance the search for new immune-based treatments for this deadly disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.